Expert Perspectives on Novel Combination Therapy in Newly Diagnosed Myeloma

Panelists discuss how quadruplet therapy has become the new benchmark for NDMM, offering deeper and more durable responses than previous triplet regimens.

Panelists discuss how risk stratification using cytogenetic and molecular markers is vital to tailoring NDMM therapy and improving long-term outcomes.

Panelists discuss how comprehensive diagnostic and functional pretesting ensures safe and effective initiation of quadruplet therapy in NDMM.

Panelists discuss how the ADVANCE study was structured to determine whether adding daratumumab to KRd enhances depth and durability of response in NDMM.

Panelists discuss how the ADVANCE trial’s inclusive design and MRD-based end points make it a model for future NDMM research.

Panelists discuss how ADVANCE results show daratumumab-based quadruplets achieve high MRD negativity across risk and age groups in NDMM.

Panelists discuss how ADVANCE findings support the use of quadruplet therapy in both transplant-eligible and -ineligible patients with NDMM.

Panelists discuss how daratumumab plus KRd demonstrates manageable toxicity and strong real-world feasibility with appropriate supportive care.

Panelists discuss how infection prevention and selective IVIG use are critical for maintaining safety during NDMM combination therapy.

Panelists discuss how evolving MRD-driven and immune-based therapies are shaping a personalized future for NDMM management.